• Louise Chen from Scotiabank sets a price target of $60 for BMY, indicating a potential 7.40% increase.
• BMY's stock has risen by 17.3% over the past six months, showcasing strong performance despite challenges.
• The company has raised its revenue guidance following high demand for its products, although it anticipates a decline in its legacy portfolio due to generics.

Bristol Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company known for its innovative medicines. It focuses on areas like oncology, immunology, and cardiovascular diseases. The company competes with other major players in the biotech industry, such as Pfizer and Merck. On January 9, 2026, Louise Chen from Scotiabank set a price target of $60 for BMY, suggesting a potential 7.40% increase from its current price of $55.87.

BMY has seen a significant rally, with its stock rising by 17.3% over the past six months. This growth, while slightly behind the biotech industry's 23.4% increase, has surpassed the broader sector and the S&P 500. The company's strong third-quarter results, reported on October 30, have played a key role in this upward trend. High demand for products like Opdivo, Breyanzi, Reblozyl, and Camzyos has driven these results.

In light of its strong performance, Bristol Myers has raised its revenue guidance. However, the company expects a 15-17% decline in its legacy portfolio in 2025 due to the impact of generics on older drugs. Despite these challenges, the recent stock rally has helped restore investor confidence in BMY. The current stock price is $55.84, reflecting a slight decrease of 0.12% or $0.07.

BMY's stock has fluctuated between a low of $55.62 and a high of $56.35 during the day. Over the past year, it has reached a high of $63.33 and a low of $42.52. The company has a market capitalization of approximately $113.67 billion. Today's trading volume for BMY is 2,385,562 shares, indicating active investor interest.